Angiotensin Type 1 Receptor Antagonists are a class of pharmaceutical drugs primarily used in the management of hypertension and certain cardiovascular conditions. They work by blocking the angiotensin II receptor, which helps dilate blood vessels and reduces fluid retention, leading to decreased blood pressure. Additionally, they find application in the treatment of heart failure and diabetic nephropathy, as they help protect the kidneys from the damaging effects of high blood pressure. According to the World Health Organization (WHO), hypertension affects over 30% of the adult population in Europe and approximately 45% in the USA. Cardiovascular diseases remain the leading cause of death globally, responsible for about 4 million deaths in Europe and 650,000 deaths in the USA annually. Hypertension-related complications, such as stroke and heart attacks, account for a significant portion of these fatalities. Furthermore, heart failure prevalence is estimated to affect around 2% of the European population and 2.5% of the US population.
The growth drivers of the Angiotensin Type 1 Receptor Antagonist market include increasing awareness of hypertension-related risks and its association with cardiovascular diseases. Advancements in drug development, formulation, and patient-centric approaches contribute to the market's expansion. Companies such as Boryung Group, Daewoong Pharma, Allist, Alvogen, Autotelic, Chong Kun Dang, Daiichi Sankyo, Dimerix, Generic mfg., Ildong, and JW Pharma are pharmaceutical companies operating in the healthcare industry. cater to this category. Moreover, many companies are coming up with new molecules in this space.
Key Developments
- In July 2023, JW Pharmaceutical launched Livasartan for Hyperlipidaemia in South Korea
- In July 2023, JW Pharmaceutical launched Livasartan for Hypertension in South Korea
Approved Angiotensin Type 1 Receptor Antagonist molecules
- Azilva (azilsartan)
- Cantabell (amlodipine, candesartan cilexetil)
- Aprovasc (amlodipine, irbesartan)
- rosuvastatin, telmisartan
- Livasartan (pitavastatin, valsartan)
- Tuvero (fimasartan, rosuvastatin)
- Olostar (rosuvastatin, olmesartan medoxomil)
- Xinlitan (allisartan)
- Dukaro (amlodipine, fimasartan, rosuvastatin)
- Telotan (rosuvastatin, telmisartan)
- Rocanduo (candesartan cilexetil, rosuvastatin calcium)
- Rovatitan (rosuvastatin, valsartan)
Angiotensin Type 1 Receptor Antagonist Pipeline Molecules
- Amlodipine, candesartan (HL-068)
- Sacubatril, allisartan (S086)
- Dapagliflozin, olmesartan medoxomil (ATB-101)
- Irbesartan, propagermanium (DMX-200)
Clinical Activity and Development of Angiotensin Type 1 Receptor Antagonist
In the Angiotensin Type 1 Receptor Antagonist space, there are very few companies conducting more than 50 clinical trials in this category of drugs. For instance,
- In May 2021, Takeda initiated a phase III trial of Azilsartan for Hypertension (In children) in Japan, estimated to be completed in December 2023.
- In May 2022, Dimerix Bioscience initiated Phase-III clinical trials of Irbesartan/propagermaniumin focal segmental glomerulosclerosis (adjunctive treatment, In the elderly, In adults) in France, Argentina, Australia, Brazil, Hong Kong, New Zealand, Taiwan, Spain, United Kingdom
|
Product Name |
Total Studies |
|
Amlodipine, candesartan (HL-068) |
2 |
|
Sacubatril, allisartan (S086) |
2 |
|
Dapagliflozin, olmesartan medoxomil (ATB-101) |
1 |
|
Irbesartan, propagermanium (DMX-200) |
6 |
Target Indication Analysis of Angiotensin Type 1 Receptor Antagonist
Angiotensin Type 1 Receptor Antagonists, also known as angiotensin receptor blockers (ARBs), are a class of medications used to treat various cardiovascular conditions. Their target indication is primarily the management of hypertension (high blood pressure) by blocking the angiotensin II receptor, leading to vasodilation and decreased fluid retention, resulting in lowered blood pressure. Additionally, they are employed in the treatment of certain heart conditions, such as heart failure, and diabetic nephropathy, as they help protect the kidneys from the damaging effects of high blood pressure. ARBs are an essential component of cardiovascular therapy, particularly for patients with specific risk factors.
Regional Analysis of Angiotensin Type 1 Receptor Antagonist
Angiotensin Type 1 Receptor Market
The global Angiotensin Type 1 Receptor Antagonist market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The US regional market for angiotensin type 1 receptor antagonists in the pharmaceutical sector has exhibited steady growth over recent years. With a high prevalence of hypertension and cardiovascular diseases, the demand for these drugs remains strong. Additionally, an aging population and lifestyle factors contribute to the sustained market demand. The market is dominated by established pharmaceutical companies, but there is also a presence of generic manufacturers due to patent expirations. Adherence to strict regulatory requirements and clinical guidelines significantly influences market dynamics. The growth of the Angiotensin Type 1 Receptor Antagonist market is primarily driven by factors such as increasing awareness about hypertension management and its related complications. Advancements in drug development and formulation, leading to improved efficacy and reduced side effects, further propel market expansion. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for Angiotensin Type 1 Receptor Antagonists. These countries are increasingly adopting Angiotensin Type 1 Receptor Antagonists due to their efficacy and potential to improve patient outcomes. On the other hand, the Angiotensin Type 1 Receptor Antagonist market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the Angiotensin Type 1 Receptor Antagonist market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Angiotensin Type 1 Receptor Antagonist drugs are used in the management of heart failure and diabetic nephropathy.
The growth of the Angiotensin Type 1 Receptor Antagonist market is primarily driven by factors such as increasing awareness about hypertension management and its related complications. Advancements in drug development and formulation, leading to improved efficacy and reduced side effects, further propel market expansion.
The major players in this space are Boryung Group, Daewoong Pharma, Allist, Alvogen, Autotelic, Chong Kun Dang, Daiichi Sankyo, Dimerix, Generic mfg., Ildong, and JW Pharma are pharmaceutical companies operating in the healthcare industry.
Some of the key restraints affecting the Angiotensin Type 1 Receptor Antagonist market include increasing competition from other classes of antihypertensive drugs and the potential for side effects and contraindications in certain patient populations. Additionally, the expiration of patents for some Angiotensin Type 1 Receptor Antagonists has led to the entry of generic versions, impacting market revenues for branded drugs.
- Boryung Group
- Daewoong Pharma
- Allist
- Alvogen
- Autotelic
- Chong Kun Dang
- Daiichi Sankyo
- Dimerix
- Generic mfg.
- Ildong
- JW Pharma
- Jeil
- LG Chem
- Materia Medica
- Merck (MSD)
- Sanofi
- Shenzhen Salubris
- Shionogi
- Simcere
- Sumitomo Pharma
- Takeda